HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Health Product Market Fraud During Pandemic Didn’t Surprise US FDA – Woodcock

Executive Summary

“This type of activity always emerges during a crisis where people will take advantage of others’ desperation and fear,” says acting Commissioner Janet Woodcock in FDLI conference keynote. Regulated industries’ data are needed to continue responding to COVID-19 and prepare for “what comes next.”

You may also be interested in...



US Businessman Ignores Federal, State Regulators’ Warnings, Faces Criminal COVID-19 Fraud Charges

Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.

False COVID-19 Claims In US Consumer Health Market: Rampant With Forecast For More

In addition to 45 businesses with varying levels of communication skills the FTC targeted in its latest batch of warnings about false advertising linked coronavirus, the FDA "sent hundreds of abuse complaints to domain name registrars and internet marketplaces" also linked to bogus COVID-19 claims.

Progress On Adding OTC Drugs To US Market? Room To Move But Label Format Limits Options

Changes for supporting OTC labeling for drugs currently available Rx-only and indicated for chronic, more complicated conditions, aren’t minor and won’t happen within limits of one-dimensional text media printed on OTC drug containers, packages and inserts.

Topics

UsernamePublicRestriction

Register

RS151341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel